Cargando…
Clinical experience with live-attenuated, double-deleted (LADD) listeria monocytogenes targeting mesothelin-expressing tumors
Autores principales: | Brockstedt, Dirk G, Le, Dung T, Hassan, Raffit, Murphy, Aimee, Grous, John, Dubensky, Thomas W, Jaffee, Elizabeth M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991217/ http://dx.doi.org/10.1186/2051-1426-1-S1-P203 |
Ejemplares similares
-
Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
por: Hassan, Raffit, et al.
Publicado: (2015) -
Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas
por: Crittenden, Marka, et al.
Publicado: (2015) -
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer
por: Drake, Charles G., et al.
Publicado: (2021) -
Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018) -
A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study)
por: Wang-Gillam, Andrea, et al.
Publicado: (2014)